main-img
Back to Home » November 2016 News » CV Sciences, Inc. Reports Third Quarter 2016 Financial Results

CV Sciences, Inc. Reports Third Quarter 2016 Financial Results

November 02, 2016

Company Continues Advancing its Preclinical Drug Development Program to Address the Multi-Billion Dollar Treatment Market Opportunity to Support Cessation of Smokeless Tobacco Use and Addiction; Company to Hold Webcast November 10, 2016 to Discuss Development Efforts and Potential of its Proprietary Lead Drug Candidate, CVSI-007; Consumer Products Division Reported Sales of $2.94 Million for Q3 2016

Source URL: http://www.marketwired.com/mw/release.do?id=2171821&sourceType=3
Browse News